Klinische Studie

Post-authorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with ZEJULA® (niraparib) (PASS)(PASS)Post-authorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia in cancer receiving maintenance treatment with ZEJULA® (niraparib) (PASS)
Krankheitsentität(en) Weibliches Genital (z.B. Eierstock, Eileiter, Gebärmutter, Scheide, Schamlippen)
StudientypBeobachtungsstudie
Wesentliche EinschlusskriterienPatient must have a diagnosis of platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Wesentliche AusschlusskriterienPatient receiving niraparib for use that is not according to approved authorized indication.
StatusStudie beendet
Ansprechpartner & KontaktCaritas-Krankenhaus St. Josef RegensburgFrauenheilkunde und Geburtshilfe Krankenhaus St JosefStudienzentrale0941 7823401fhk-studienzentrum(at)csj.de
zurück